Active Ethanol

Phase 1Small molecule

YYale University

Active Ethanol is one of 57 small molecule programs targeting Cognition. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CognitionActive, not recruiting

ExperimentalRecruiting

CognitionPhase 1

Active, not recruiting

ExperimentalPhase 1

Recruiting

Competition

Competitive Landscape

85 competitors in Cognition

#DrugCompanyPhaseTrials

Xarelto

WWim Janssens

Approved

1 2

Neurontin

VViatris Specialty LLC

Approved

1 3

Ambien

PPurdue Pharma LP

Approved

1 4

Accutane

CConrado Roberto Hoffmann Filho

Approved

1 5

Zanaflex

LLegacy Health System

Approved

—6

Osmitrol

BB. Braun Medical Inc.

Namenda

3 8

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 2

1 9

Remimazolam Tosilate

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

1 10

Psilocybin

COMPASS Pathways

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Experimental

NCT07434895

Clinical

Trials by Indication[1]

Cognition4 trials

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

Active, not recruiting·YYale University·Phase 1·NCT02404688·40 enrolled

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III

Active, not recruiting·YYale University·Phase 1·NCT02710331·40 enrolled

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I

Active, not recruiting·YYale University·Phase 1·NCT02709954·40 enrolled

Show 1 more trial

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II

Active, not recruiting·YYale University·Phase 1·NCT02710097·40 enrolled

Marijuana1 trial

Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products

Completed·YYale University·Phase 1·NCT04226690·24 enrolled

Immune1 trial

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans

Completed·YYale University·Phase 1·NCT04920539·56 enrolled

Psychosis1 trial

THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

Completed·YYale University·Phase 1·NCT04199468·22 enrolled

Humans1 trial

Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans

Completed·VVA Office of Research and Development·Phase 1·NCT01590277·33 enrolled

2 more indications

Experimental1 trial

The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study

Recruiting·HHannah Harris·Phase 1·NCT07434895·23 enrolled

Unspecified2 trials

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

Completed·YYale University·Phase 1·NCT02576912·38 enrolled

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

Completed·YYale University·Phase 1·NCT02811939·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Active Ethanol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Active Ethanol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Active Ethanol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: YYale University

Active Ethanol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Cognition4 trials

Marijuana1 trial

Immune1 trial

Psychosis1 trial

Humans1 trial

Experimental1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News